Glucose restriction decreases telomerase activity and enhances its inhibitor response on breast cancer cells: Possible extra-telomerase role of BIBR 1532

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Wardi, Layal ^a   Alaaeddine, Nada ^a   Raad, Issam ^b   Sarkis, Riad ^c   Serhal, Rim ^a   Khalil, Charbel ^a   Hilal, George ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

BIBR 1532; Breast cancer; Cancer; Glucose restriction; Telomerase

Indexed keywords

ANNEXIN; BIBR 1532; CASPASE 3; GLUCOSE; MESSENGER RNA; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GLUCOSE RESTRICTION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MITOCHONDRIAL RESPIRATION; NITROBLUE TETRAZOLIUM TEST; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; BREAST CANCER CELL LINE; PROTEIN EXPRESSION;

EID: 84905378600     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-60     Document Type: Article

References (38)

1. Osborne TB, Mendel LB, Ferry EL. The effect of retardation of growth upon the breeding and duration of life of rats. Science 1917, 45:294-295.
2. Martin B, Golden E, Egan JM, Mattson MP, Maudsley S. Reduced energy intake: the secret to a long and healthy life?. IBS J Sci 2007, 2:35-39.
3. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 2010, 31:89-98.
4. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
5. Fontana L, Klein S. Aging, adiposity, and calorie restriction. JAMA J Am Med Assoc 2007, 297:986-994.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
7. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004, 4:519-527.
8. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009, 53:171-184.
9. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: a case series report. Aging 2009, 1:988-1007.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
11. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett 2004, 564:9-13.
12. Autexier C, Lue NF. The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 2006, 75:493-517.
13. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26:867-874.
14. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003, 54:131-152.
15. Grizzi F, Di Ieva A, Russo C, Frezza EE, Cobos E, Muzzio PC, Chiriva-Internati M. Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model 2006, 3:37.
16. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
17. Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell 2008, 134:703-707.
18. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
19. Hammerman PS, Fox CJ, Thompson CB. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci 2004, 29:586-592.
20. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000, 28:669-677.
21. Klement RJ, Kämmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer?. Nutr Metab 2011, 8:75.
22. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008, 68:5492-5499.
23. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
24. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab 2010, 7:7.
25. Li Y, Liu L, Tollefsbol TO. Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB J Off Publ Fed Am Soc Exp Biol 2010, 24:1442-1453.
26. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 2002, 277:15566-15572.
27. Janjic D, Wollheim CB. Islet cell metabolism is reflected by the MTT (tetrazolium) colorimetric assay. Diabetologia 1992, 35:482-485.
28. Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993, 303:474-482.
29. Pantic M, Zimmermann S, El Daly H, Opitz OG, Popp S, Boukamp P, Martens UM. Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells. Oncogene 2006, 25:4413-4420.
30. Pantic M, Zimmermann S, Waller CF, Martens UM. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line. Int J Oncol 2005, 26:1227-1232.
31. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010, 47:87-95.
32. Sauer LA, Dauchy RT. Stimulation of tumor growth in adult rats in vivo during acute streptozotocin-induced diabetes. Cancer Res 1987, 47:1756-1761.
33. Brookes PS. Mitochondrial proton leak and superoxide generation: an hypothesis. Biochem Soc Trans 1998, 26:S331.
34. Oyedotun KS, Lemire BD. The quaternary structure of the Saccharomyces cerevisiae succinate dehydrogenase. Homology modeling, cofactor docking, and molecular dynamics simulation studies. J Biol Chem 2004, 279:9424-9431.
35. Apel K, Hirt H. Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 2004, 55:373-399.
36. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang J, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
37. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006, 5:577-584.
38. Zhou C, Steplowski TA, Dickens HK, Malloy KM, Gehrig PA, Boggess JF, Bae-Jump VL. Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cells. PLoS One 2013, 8:e55730.